What is Cidara Therapeutics Inc (CDTX) stock price today?

Cidara Therapeutics Inc (CDTX) currently trades at $221.38 per share. The stock has a market capitalization of $6.96B and a P/E ratio of —x.

Is CDTX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Cidara Therapeutics Inc has a Smart Value Score of 23/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -3.88.

Is Cidara Therapeutics Inc financially healthy?

Cidara Therapeutics Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -3.88 places it in the distress.

CDTX

Cidara Therapeutics Inc

NASDAQ: CDTX · HEALTHCARE · BIOTECHNOLOGY

$221.38

+0.00% today

Updated 2026-01-07

Market cap

$6.96B

P/E ratio

—

P/S ratio

4,540.70x

EPS (TTM)

$-11.20

Dividend yield

—

52W range

$15 – $221

Volume

1.5M

Market cap

$6.96B

P/E ratio

—

P/S ratio

4,540.70x

EPS (TTM)

$-11.20

Dividend yield

—

52W range

$15 – $221

Volume

1.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-3.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$221.50

+0.05%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy1 Buy6 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.00x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -3.88 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-40.62M

- Revenue declining -1.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2021	2022	2023	2024	TTM
Revenue	$49.57M	$64.29M	$23.28M	$1.27M	$0.00
Net income	$-43.91M	$-29.80M	$-22.93M	$-169.83M	$-83.23M
EPS	—	—	—	—	$-11.20
Free cash flow	$-25.27M	$-28.59M	$-22.94M	$-176.66M	$-40.62M
Profit margin	-88.58%	-46.35%	-98.49%	-13,319.76%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CDTX	$6.96B	23	2.7	3.0	5.0	6.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Cidara Therapeutics Inc trades at $221.38. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -3.88, it sits in the distress.

Frequently asked questions

What is Cidara Therapeutics Inc's stock price?

Cidara Therapeutics Inc (CDTX) trades at $221.38.

Is Cidara Therapeutics Inc overvalued?

Smart Value Score 23/100 (Grade F, Strong Sell).

What is the price target of Cidara Therapeutics Inc (CDTX)?

The analyst target price is $221.50, representing +0.1% upside from the current price of $221.38.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-3.88 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio4,540.70x

ROE-0.69%

Beta1.53

50D MA$196.94

200D MA$89.05

Shares out0.03B

Float0.02B

Short ratio—

Avg volume1.5M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

CDTX vs LLY →CDTX vs JNJ →CDTX vs ABBV →Stock screener →